New insider activity at Supernus Pharmaceuticals ( (SUPN) ) has taken place on September 8, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
President & CEO Jack Khattar has recently sold 55,578 shares of Supernus Pharmaceuticals stock, amounting to a significant transaction valued at $2,557,143.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals demonstrates strong financial health and technical momentum, supported by strategic acquisitions. However, high valuation and patent challenges pose risks. The company’s robust cash flow and operational efficiency are key strengths, but attention to revenue growth and cost management is crucial for sustaining long-term performance.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
YTD Price Performance: 26.27%
Average Trading Volume: 831,614
Technical Sentiment Signal: Buy
Current Market Cap: $2.58B